The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in serum and urine until 12 months in Patients with Multiple Myeloma Treated With intravenous bisphosphonates in routine care.
Study Type
OBSERVATIONAL
Enrollment
3
collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
Necker Hospital, Adult haematology department
Paris, France
Changes in bone turnover markers
bone turnover markers include: C-terminal telopeptides of type I collagene (CTX) in serum, amino-terminal telopeptide of type 1 collagen (NTX) in urine, Dickkopf-1 (DKK-1) and Sclerostin (SOST) in plasma
Time frame: Baseline, then every 2 months in 12 months
time to maximum variation of bone turnover markers
CTX, NTX, DKK-1 and SOST
Time frame: Baseline, then every 2 months in 12 months
Doses of intravenous bisphosphonate
To study the relationship between doses and bone turnover markers
Time frame: Up to 12 months
Rate of intravenous bisphosphonate
To study the relationship between doses and bone turnover markers
Time frame: Up to 12 months
evolution of bone lesions by imaging
evolution of bone lesions by imaging
Time frame: Up to 12 months
Number of new bone events
Time frame: Up to 12 months
Number of adverse events likely to be related to bisphosphonate
Time frame: Up to 12 months
Changes in Monoclonal protein
To evaluated response to treatment
Time frame: Baseline, then every 2 months in 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.